Kalaris Therapeutics Inc (KLRS) Research

Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.

Market snapshot

Symbol
KLRS
Price
$4.72
Day change
+3.74%
Market cap
$88.3M
P/E ratio
-2.54x
52-week range
2.14-11.88
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$18.25

Peer companies

  • Artiva Biotherapeutics, Inc. (ARTV)
  • Connect Biopharma Holdings Limited (CNTB)
  • Context Therapeutics Inc. (CNTX)
  • InflaRx N.V. (IFRX)
  • ImageneBio Inc (IMA)
  • Metagenomi, Inc. Common Stock (MGX)
  • Ovid Therapeutics Inc. (OVID)
  • Quince Therapeutics, Inc. (QNCX)

Recent insider activity

  • Jovan-Embiricos Morana — A-Award (9000 shares) on 2026-06-03
  • Ferrara Napoleone — A-Award (9000 shares) on 2026-06-03
  • Hallal David — A-Award (9000 shares) on 2026-06-03
  • AKKARAJU SRINIVAS — A-Award (9000 shares) on 2026-06-03
  • Dybbs Michael — A-Award (9000 shares) on 2026-06-03

Open Kalaris Therapeutics Inc (KLRS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.